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Research
Millions of people worldwide are exposed to 
arsenic in their drinking water, and arsenic is a 
well-documented cause of many serious health 
effects. The International Agency for Research 
on Cancer (2004) classified arsenic in drinking 
water as carcino genic to humans, based on evi-
dence that arsenic causes cancers of the skin, 
lung, and bladder. Chronic arsenic exposure 
has also been shown to cause non cancer health 
outcomes in multiple organs, including repro-
ductive, cardio vascular, pulmonary, neuro-
logic, and dermal effects (National Research 
Council 1999, 2001). In the present study we 
investigated all causes of death following prob-
able in utero and early-life exposure to arsenic. 
We examined mortality in an area in 
northern Chile that has some unique features 
that make it an ideal location to study long-
term outcomes from arsenic exposure. It is 
the driest inhabited place on earth (McKay 
et al. 2003). Because it had no private wells, 
all residents drank water from the only avail-
able source: the city water supply. Antofagasta 
obtained drinking water from rivers that flow 
from springs in the Andes Mountains. Before 
1958, the arsenic level of the city water supply 
was about 90 µg/L. In 1958, a new city water 
supply was installed using water from the 
Toconce and Holajar rivers, which contained 
800 and 1,300 µg/L of arsenic, respectively 
(Smith et al. 1998). With these new sources 
of water, the average arsenic concentration in 
the city water supply increased dramatically to 
870 µg/L. After a water treatment plant was 
installed in 1970, the arsenic concentration 
in the city water supply dropped to 110 µg/L 
for about 10 years and was reduced further 
thereafter. The water supply now contains 
< 10 µg/L of arsenic.
In previous studies of mortality among 
adults 30–49 years of age, we discovered 
increased mortality due to lung cancer and 
bronchiectasis (Smith et al. 2006), kidney 
cancer (Yuan et al. 2010), and acute myo cardial 
infarction (Yuan et al. 2007) among residents 
born during or shortly before the high-exposure 
period. We therefore decided to extend our 
analysis to assess mortality from all causes of 
death among adults 30–49 years of age who 
were born during or before the high-exposure 
period. Because the age range of 30–49 years 
is a young age at which to die, we refer to these 
deaths as deaths in “young adults.”
Methods
We previously reported the methods used for 
mortality studies in northern Chile (Smith et al. 
2006; Yuan et al. 2010). In brief, we obtained 
computerized mortality data for 1989–2000 
from the Ministry of Health (Santiago, Chile) 
for all 13 regions of Chile. Deaths were divided 
into two groups: residents of Antofagasta 
and neighboring Mejillones (cities located in 
Region II of Chile that have the same water 
source), and residents in all other regions of 
Chile. Antofagasta is very much larger than 
Mejillones, so here we refer to Antofagasta 
and Mejillones combined as Antofagasta. We 
selected 1989 as the first year because it is the 
first year for which deaths in Antofagasta were 
reported separately from the rest of Region II. 
Other parts of Region II also had arsenic in 
drinking water, although to a lesser extent than 
Antofagasta. Outside of Region II, the rest of 
Chile has not been exposed to high levels of 
arsenic in drinking water. With rare exceptions, 
arsenic concentrations in water sources outside 
of Region II have been < 10 µg/L. In a 1984 
nationwide survey of 2,000 people, average 
urine arsenic concentrations were 14 µg/L 
(Venturino 1991). This is similar to average 
levels found in the general U.S. population 
(16.7 µg/L) and indicates very low arsenic 
concentrations in drinking water (Steinmaus 
et al. 2009). In addition to mortality data, we 
obtained survey and census data comparing 
variables such as smoking, diet, and socio-
economic status from Antofagasta and the 
rest of Chile in order to evaluate potential 
confounding from these factors.
In the present study, we focused on deaths 
during 1989–2000 among people 30–49 years 
of age from Antofagasta or from all of Chile 
except Region II (referents). People from 
Antofagasta in this age range would have been 
in utero, children, or adolescents (up to 18 years 
of age) during at least part of the high-exposure 
period of 1958–1970. Two birth cohorts were 
defined for this investigation: births during 
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Background: Beginning in 1958, the city of Antofagasta in northern Chile was exposed to high 
arsenic concentrations (870 µg/L) when it switched water sources. The exposure abruptly stopped in 
1970 when an arsenic-removal plant commenced operations. A unique exposure scenario like this—
with an abrupt start, clear end, and large population (125,000 in 1970), all with essentially the 
same exposure—is rare in environmental epidemiology. Evidence of increased mortality from lung 
cancer, bronchiectasis, myocardial infarction, and kidney cancer has been reported among young 
adults who were in utero or children during the high-exposure period. 
oBjective: We investigated other causes of mortality in Antofagasta among 30- to 49-year-old 
adults who were in utero or ≤ 18 years of age during the high-exposure period. 
Methods: We compared mortality data between Antofagasta and the rest of Chile for people 
30–49 years of age during 1989–2000. We estimated expected deaths from mortality rates in all 
of Chile, excluding Region II where Antofagasta is located, and calculated standardized mortality 
ratios (SMRs).
results: We found evidence of increased mortality from bladder cancer [SMR = 18.1; 95% con-
fidence interval (CI): 11.3, 27.4], laryngeal cancer (SMR = 8.1; 95% CI: 3.5, 16.0), liver cancer 
(SMR = 2.5; 95% CI: 1.6, 3.7), and chronic renal disease (SMR = 2.0; 95% CI: 1.5, 2.8).
conclusions: Taking together our findings in the present study and previous evidence of increased 
mortality from other causes of death, we conclude that arsenic in Antofagasta drinking water has 
resulted in the greatest increases in mortality in adults < 50 years of age ever associated with early-
life environmental exposure. 
key words: arsenic, childhood exposure, Chile, drinking water, environmental exposure, 
in utero, mortality. Environ Health Perspect 120:1527–1531 (2012). http://dx.doi.org/10.1289/
ehp.1104867 [Online 4 September 2012]
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1958–1970 (probable in utero and childhood 
exposure to those born in Antofagasta), and 
births during 1940–1957 (probable childhood, 
but not in utero, exposure to those born in 
Antofagasta). 
The Ministry of Health coded causes of 
death for 1989–1998 using the International 
Classification of Diseases, 9th Revision (ICD-9; 
World Health Organization 1978) and for 
1999–2000 using the 10th revision (ICD-10; 
World Health Organization 1992). For our 
analysis, we converted all ICD-10 codes into 
ICD-9 codes. In our initial analysis, we noticed 
that several causes of death listed under ICD-9 
codes 580–589 (genito urinary) exhibited ele-
vated standardized mortality ratios (SMRs). 
The excess deaths were limited to chronic renal 
failure (ICD-9 code 585), renal failure unspeci-
fied (ICD-9 code 586), chronic glomerulo-
nephritis (ICD-9 code 582), and renal sclerosis 
(ICD-9 code 587). Because each of these 
causes of death relates to chronic renal disease 
and renal failure, we grouped them together as 
mortality from chronic renal disease. 
We obtained annual estimates of the popu-
lation living in Antofagasta in Region II, as well 
as for the rest of Chile excluding Region II, 
for 1989–2000 from the National Institute of 
Statistics (Instituto Nacional de Estadísticas); 
estimates were stratified by age and sex. We 
calculated SMRs for deaths among those 
30–49 years of age, using 10-year age groups 
(30–39 and 40–49 years) for age standardi-
zation. We calculated significance and con-
fidence intervals (CIs) based on the Poisson 
distribution (Selvin 1995). In view of the clear 
direction of the a priori hypotheses for arsenic 
causing increased risks for both malignant and 
non malignant diseases, here we present one-
tailed tests of statistical significance. We tested 
for effect modification by age group (comparing 
30- to 39-year and 40- to 49-year age groups) 
and effect modification by sex using Poisson 
regression inter action terms with two-tailed 
tests. We also tested for effect modification by 
birth period, comparing mortality for those 
born in 1940–1949 with those born in 1950–
1957, but because there were no significant 
differences by birth period for any outcome 
(p > 0.05), we report results for both periods 
combined. We compared mortality at 30–49 
years of age among those born in 1940–1957, 
who would have experienced at least part of 
their exposure ≤ 18 years of age, with mortality 
among those born during 1958–1970, most of 
whom would have been exposed in utero if they 
were born in Antofagasta.
Results
Based on a 1990 random sample survey of 
Chilean cities that included Antofagasta 
[Caracterizacion Socio Economica Nacional; 
(CASEN) 1990], the prevalence of smoking 
in 1990 was comparable between Antofagasta 
and the rest of Chile (Table 1). Demographic 
characteristics for Region II from the 2002 
Census (Instituto Nacional de Estadisticas 
Chile 2002) are similar for Region II and 
Chile as a whole, including the percentage 
of the population living in urban areas (98% 
and 87%, respectively) and the percentage 
of medically certified death certificates (90% 
and 86%). Diet and other health risk factors 
collected in studies of stratified random 
population census samples conducted in 2003 
and 2009 (Gobierno de Chile, Ministerio de 
Salud 2003, 2010), including obesity, blood 
cholesterol, glucose, and hypertension, were also 
similar between the comparison populations.
We first estimated SMRs comparing spe-
cific causes of death among adults 30–49 years 
of age born in Antofagasta during 1940–1970 
(both sexes combined) to the same age group 
born in the rest of Chile (data not shown). We 
observed no increased mortality from infectious 
and parasitic diseases (ICD-9 codes 001–139; 
SMR = 1.0; 95% CI: 0.8, 1.3), endocrine and 
nutritional diseases (ICD-9 codes 240–279; 
SMR = 1.2; 95% CI: 0.7, 1.8), for diseases of 
the respiratory system (ICD-9 codes 460–519; 
SMR = 1.1; 95% CI: 0.9, 1.3), or diseases of 
the digestive system (ICD-9 codes 520–579; 
SMR = 0.8; 95% CI: 0.7, 0.9). Mortality was 
increased for all cancers combined (ICD-9 
codes 140–239; SMR = 1.7; 95% CI 1.6, 1.9; 
p < 0.001), deaths from circulatory diseases 
(ICD-9 codes 390–459; SMR = 1.7; 95% CI: 
1.5, 2.0; p < 0.001), and diseases of the genito-
urinary system (ICD-9 codes 580–629; 
SMR = 2.0; 95% CI: 1.5, 2.8; p < 0.001). 
Table 2 presents the SMRs for selected 
causes of death in Antofagasta for males and 
females 30–49 years of age during 1989–2000 
and the expected numbers estimated from 
those in the rest of Chile (excluding Region II). 
The “all other cancers” category comprises all 
cancers other than those of the bladder, larynx, 
and liver, as well as lung and kidney cancers, 
which we previously reported to be associated 
with early-life arsenic exposure (Smith et al. 
2006; Yuan et al. 2010). Mortality for all 
cancers combined was increased for males 
born during 1940–1957, most of whom 
would have experienced at least some exposure 
before 18 years of age (SMR = 2.1; 95% CI: 
1.9, 2.4; p < 0.001), and for those born during 
the high-exposure period (1958–1970), 
most of whom would have experienced both 
in utero and childhood exposure (SMR = 2.2; 
95% CI: 1.7, 2.8; p < 0.001). Mortality from 
all cancers combined was also increased among 
females (SMR = 1.4; 95% CI: 1.2, 1.6 and 
SMR = 1.4; 95% CI: 1.1, 1.8 for those born 
in 1940–1957 and 1958–1970, respectively), 
but to a lesser extent than in males. 
Mortality from bladder cancer was greatly 
increased in males and females (Table 2), par-
ticularly among those born during 1958–1970, 
Table 1. Comparing smoking data, demographic variables, and risk factors for Region II (of which 
Antofagasta constitutes more than half of the total population) with those for all of Chile.
Variable Region II All of Chile
Smoking (%)a
Nonsmokers 78.0 77.5
Moderate smokers (> 0 to 1 pack/day) 21.0 21.1
Heavy smokers (> 1 pack/day) 1.0 1.2
Men smokers 27.4 26.6





Prebasic education 4 4
University/professional education 17 14
Death certificate certified by physician 90 86
Medical risk factorc
Average BMI (kg/cm2) 27.6 26.8
Obese [BMI > 30 (%)] 19.2 21.9
Morbidly obese [BMI > 40 (%)] 2.8 1.3
Average HDL cholesterol (mg/dL) 34.2 44.6
Average LDL cholesterol (mg/dL) 105.0 115.4
Hypertension [blood pressure > 140/90 (%)] 28.9 33.5
Average total cholesterol (mg/dL) 174.0 186.0
Average serum glucose (mg/dL) 85.8 92.9
Diabetes (%) 3.2 4.2
Regular exercise (%) 13.8 9.2
Dietary risk factor in national surveyd
Alcohol consumed per day (g) 41.5 55.6
Fruit/vegetables consumed per day (g) 174.0 186.0
Salt consumption/day (g) 173.8 185.8
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein. 
aData from CASEN (1990). bData from Instituto Nacional de Estadisticas Chile (2002). cData from Gobierno de Chile, 
Ministerio de Salud (2003). dData from Gobierno de Chile, Ministerio de Salud (2010). 
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the high-exposure period with probable expo-
sure in utero (for males, SMR = 65.7; 95% CI: 
24.1, 143; for females, SMR = 43.0; 95% CI: 
8.9, 126; p = 0.01 for inter action between 
birth periods 1940–1957 and 1958–1970 
for males and females combined, adjusted for 
sex). Increases in liver cancer mortality were 
also more pronounced for those born during 
1958–1970 (for males, SMR = 5.9; 95% CI: 
1.9, 13.7; for females, SMR = 4.7; 95% CI: 
1.3, 12.0; p = 0.04 for interaction by birth 
period among males and females combined). 
Mortality from laryngeal cancer was increased 
among men born in 1940–1957, before the 
high-exposure period (SMR = 8.9; 95% CI: 
3.6, 18.3).
Among non cancer causes of death for 
adults 30–49 years of age, we observed evi-
dence of increased mortality from chronic 
renal disease, with SMRs in the range of 
1.9–2.5 for men and women born during or 
before the high-exposure period (Table 2).
When data for both time periods were 
combined, we observed no significant differ-
ences in SMRs by sex for outcomes evaluated 
for the first time in the present study, or for 
outcomes evaluated previously using SMRs for 
different time periods or separately for men 
and women [lung cancer, bronchiectasis, and 
other chronic obstructive pulmonary disease 
(COPD) (Smith et al. 2006); acute myocardial 
infarction (Yuan et al. 2007); and kidney can-
cer (Yuan et al. 2010)] (Figure 1). The high-
est combined SMRs were for bladder cancer 
(SMR = 18.1; 95% CI: 11.3, 27.4) and bron-
chiectasis (SMR = 18.4; 95% CI: 10.3, 30.4) 
(Figure 1).
Discussion
We found increases in mortality from several 
different causes of death in the 30- to 49-year-
old study population. We previously reported 
increases in lung cancer and bronchiectasis 
in Chile following early-life arsenic exposure 
(Smith et al. 2006), as well as increases in bron-
chiectasis in India after adult exposure (Guha 
Mazumder et al. 2005). We have also reported 
increases in mortality from kidney cancer (Yuan 
et al. 2010) and myo cardial infarction (Yuan 
et al. 2007) after early-life exposure to arsenic 
in Antofagasta. Bladder cancer SMRs from the 
present analysis for adults (30–49 years of age) 
born during the high-exposure period (1958–
1970; males: SMR = 65.7; 95% CI: 24.1, 143, 
females: SMR = 43.0; 95% CI: 8.9, 126) are 
5–10 times higher than those we reported pre-
viously for all ages combined, regardless of age 
at exposure (males, 6.0; females, 8.2) (Smith 
et al. 1998).
The association between early-life exposure 
to arsenic and mortality from laryngeal can-
cer suggests that this cancer might be related 
to arsenic exposure, although the number of 
laryngeal cancer deaths was very small and the 
association was evident only among men. 
The findings concerning mortality from 
chronic renal disease were unexpected. In 
one study in Taiwan, Chiu and Yang (2005) 
reported a relation ship between arsenic and 
mortality from renal diseases, but the authors 
did not specifically investigate early-life 
exposure. In the study area in Taiwan, resi-
dents had consumed arsenic-contaminated 
well water with a median concentration of 
780 µg/L and had renal disease mortality rates 
that were 50% higher than those in unexposed 
populations. It is plausible that renal disease 
might relate to arsenic in water because arse-
nic is excreted through the kidney and is also 
a probable cause of kidney cancer (National 
Research Council 2001; Yuan et al. 2010). 
Table 2. Observed and expected deaths and SMRs for males and females 30–49 years of age during 1989–2000 and born in Antofagasta, Chile, in 1940–1957 and 
1958–1970 (during the high-exposure period). 
Cancer Sex
Born 1940–1957 Born 1958–1970 p for 
interactionb Observed Expected SMR (95% CI) p-Valuea Observed Expected SMR (95% CI) p-Valuea
All cancer Male 226 105.3 2.1 (1.9, 2.4) < 0.001 69 30.8 2.2 (1.7, 2.8) < 0.001
Female 219 154.5 1.4 (1.2, 1.6) < 0.001 59 41.3 1.4 (1.1, 1.8) < 0.01 0.83
Bladder cancer Male 11 0.8 13.7 (6.8, 24.5) < 0.001 6 0.1 65.7 (24.1, 143) < 0.001
Female 2 0.3 7.9 (1.0, 28.6) 0.03 3 0.1 43.0 (8.9, 126) < 0.001 0.01
Laryngeal cancer Male 7 0.8 8.9 (3.6, 18.3) < 0.001 1 0.0 27.4 (0.7, 153) 0.04
Female 0 0.1 — — 0 0.0 — — 0.53
Liver cancer Male 10 4.1 2.4 (1.2, 4.4) 0.01 5 0.9 5.9 (1.9, 13.7) < 0.01
Female 6 4.1 1.5 (0.5, 3.2) 0.23 4 0.9 4.7 (1.3, 12.0) 0.01 0.04
All other cancersc Male 79 82.9 1.0 (0.8, 1.2) 0.64 41 27.7 1.5 (1.1, 2.0) 0.01
Female 174 142.1 1.2 (1.0, 1.4) < 0.01 48 39.0 1.2 (0.9, 1.6) 0.09 0.36
Chronic renal diseased Male 14 7.5 1.9 (1.0, 3.1) 0.02 6 2.7 2.3 (0.8, 4.9) 0.05
Female 14 7.1 2.0 (1.1, 3.3) 0.02 6 2.4 2.5 (0.9, 5.4) 0.04 0.71
All other noncancer 
deaths minus injuriese 
Male 310 367.7 0.8 (0.8, 0.9) 0.99 110 128 0.9 (0.7, 1.0) 0.94
Female 187 178.3 1.0 (0.9, 1.2) 0.27 89 61.8 1.4 (1.2, 1.8) < 0.01 0.33
All data presented for Antofagasta include neighboring Mejillones, which had the same water sources. 
aOne-sided p-value. bTwo-sided p-value; test for interaction between birth periods 1940–1957 and 1958–1970 adjusted for sex. c“All other cancers” comprises all cancers except those of 
the bladder, larynx, liver, lung, and kidney. dICD-9 codes 580–589. e“All other non cancer deaths minus injuries” comprises all non cancer deaths except injuries, acute myocardial infarc-
tion, bronchi ectasis, and other COPD; the last three of these diseases were previously shown to be associated with early-life arsenic exposure (Smith et al. 2006; Yuan et al. 2007). 
Figure 1. Summary of SMRs for 30–49-year-old males and females (pooled) who were born in Antofagasta, 
Chile, combining those born before and during the high-exposure period (Smith et al. 2006; Yuan et al. 
2007, 2010). 
*p ≤ 0.001. **p = 0.002. #p = 0.93. 
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Adult liver cancer has been linked to arse-
nic exposure, primarily in studies in Taiwan 
(Chiu et al. 2004). In a previous study in 
Region II of Chile, we found little evidence of 
increased mortality from liver cancer in adults 
(Smith et al. 1998), but we did not evalu-
ate early-life exposure. However, in a sub-
se quent analysis of childhood cancers (Liaw 
et al. 2008), liver cancer mortality in children 
10–19 years of age was increased in Region II 
compared with Region V [for males, relative 
risk (RR) = 8.9; 95% CI: 1.7, 45.8; p = 0.009; 
for females, RR = 14.1; 95% CI: 1.6, 126; 
p = 0.018]. The data we present here are, to 
our knowledge, the first to link early-life arse-
nic exposure to liver cancer mortality in adults 
30–49 years of age.
A major strength of this study is the 
large size of the exposed population: There 
were > 125,000 residents in Antofagasta and 
Mejillones in 1970 who were exposed to water 
arsenic concentrations of 870 µg/L, including 
approximately 60,000 children with early-life 
exposure during the high-exposure period. The 
largest cohort study on arsenic conducted in 
Taiwan involved only 698 subjects ≥ 40 years 
of age exposed to arsenic concentrations 
> 300 µg/L (Chiou et al. 2001). Recently pub-
lished cohort studies in Bangladesh involved 
10,431 subjects ≥ 15 years of age exposed to 
arsenic at 300 µg/L, the largest study (Sohel 
et al. 2009), and 2,889 subjects ≥ 18 years 
of age exposed to > 150 µg/L, in the second 
largest study (Argos et al. 2010). In addition, 
the populations studied in Taiwan, India, 
and Bangladesh received their water from a 
large number of small-town or domestic wells 
with wide variations in arsenic concentrations, 
even between closely located wells (Guha 
Mazumder et al. 1998; Van Geen et al. 2002), 
making it extremely difficult to accurately esti-
mate early-life exposure decades earlier.
One potential weakness of the present 
study is that it is ecological, comparing 
Antofagasta with the rest of Chile. However, 
this study does not have the usual problems 
associated with what is sometimes termed 
the “ecologic fallacy” (Morgenstern 1995) 
because the one source of drinking water in 
Antofagasta had a known concentration of 
arsenic; therefore, we can be confident that 
virtually everyone who lived in Antofagasta 
during the high-exposure period was indeed 
exposed. Migration into and out of the study 
area could also introduce bias, but people 
migrating from Antofagasta to elsewhere in 
Chile would constitute a very small proportion 
of the total Chilean popu lation. Any resulting 
bias would tend to reduce relative mortality 
estimates for Antofagasta. Migration into 
Antofagasta also would tend to bias estimates 
toward the null because these residents would 
be mis classified as exposed even though they 
did not reside in Antofagasta during the 
high-exposure period. In addition, migration 
within Chile is relatively uncommon: From 
1965 to 2000, annual internal migration 
among regions of Chile was only 0.6% 
compared with 1.2% in Argentina, 3.1% in 
the United Kingdom, and 6.6% in United 
States (Soto and Torche 2004).
Another potential weakness of the study 
is the use of death certificate data. Based on 
Chile’s Census 2002 data (Instituto Nacional 
de Estadisticas Chile 2002), most death cer-
tificates (86%) in the country are signed by 
physicians; in Region II, where Antofagasta 
is located, the percentage is similar (90%). In 
addition, Chile has a national health care sys-
tem that services the whole country (Reichard 
1996). Therefore, it is unlikely that differences 
in diagnostic practices between Antofagasta 
and the rest of Chile would produce spurious 
differences in mortality rates.
The importance of ecological studies in 
causal inference concerning arsenic in drink-
ing water was recognized by the International 
Agency for Research on Cancer (2004): 
For most other known human carcinogens, the 
major source of causal evidence arise from case–
control and cohort studies, with little, if any, 
evidence from ecological studies. In contrast, for 
arsenic in drinking-water, ecological studies pro-
vide important information on causal inference, 
because of large exposure contrasts and limited 
population migration. 
There are two reasons why confounding 
is not a concern, the first reason of which 
involves the magnitude of the mortality rate 
ratios identified. Consider, for example, the 
SMRs for acute myo cardial infarction mortal-
ity of 2.3 and 2.7 among Antofagasta men for 
births during 1940–1957 and 1958–1970, 
respectively. These values are comparable to 
the acute myo cardial infarction mortality rate 
ratio of 2.11 for current cigarette smokers who 
smoked > 20 pack-years compared with never-
smokers from a large cohort study of about 
140,000 men in the United States (Henderson 
et al. 2007). These similarities suggest that 
confounding by smoking would explain our 
SMRs only if all men in Antofagasta smoked 
but no men in the rest of Chile smoked. 
Similarly, confounding by smoking would not 
explain the estimated SMRs for lung cancer, 
laryngeal cancer, and bladder cancer.
The second reason confounding is not a 
major concern is that there is no evidence of 
major differences in risk factors (other than 
arsenic) between Antofagasta and the rest of 
Chile. For example, a survey conducted in 
1990 indicated that the prevalence of smok-
ing in Region II (27.4% in men and 16.6% in 
women) was similar to Chile as a whole (26.6% 
in men and 19.3% in women) (Marshall et al. 
2007). It is also extremely unlikely for other 
confounding factors, including diet or exer-
cise, to produce the magnitude of the SMRs 
we report here. As shown in Table 1, other 
cardio vascular mortality risk factors, includ-
ing body mass index, obesity, cholesterol, 
and hyper tension, were not substantially dif-
ferent between Region II and all of Chile 
in 2003 (Gobierno de Chile, Ministerio de 
Salud 2003). Having given consideration to all 
potential sources of bias, we conclude that our 
study provides strong epidemiological evidence 
of increased mortality risks from several causes 
in young adults exposed to arsenic in early life.
Inorganic arsenic and its metabolites 
readily pass through the placenta, exposing 
the fetus to concentrations similar to those 
of the mother (Concha et al. 1998). Animal 
experiments have shown that arsenic is a trans-
placental carcinogen in mice and causes tumors 
in off spring (Tokar et al. 2011; Waalkes et al. 
2007). Vahter (2008) has shown that arsenic 
acts epi genetically and interferes with DNA 
methyla tion. Ren et al. (2010) reported that 
arsenic exposure may alter DNA methylation, 
globally affecting the expression of multiple 
genes; this may explain why exposure to arsenic 
is associated with multiple disease outcomes in 
different organs. 
We know of no childhood environmental 
exposure that results in comparable increases in 
adult mortality rates (Figure 1). Yorifuji et al. 
(2010) reported that mortality from pancreatic 
cancer and leukemia were increased in young 
adults after arsenic exposure from contami-
nated milk powder in Japan; these exposures 
were very high and resulted in acute poisoning 
effects. In a study of 60,182 people, Vineis 
et al. (2005) reported elevated lung cancer 
risks from childhood passive smoking, but 
the relative risk from “daily, many hours” of 
passive smoking exposure was 3.63 (95% CI: 
1.19, 11.11) and there were only four cases 
of lung cancer in this group. Other studies of 
passive childhood smoking have not found 
increased risks (Boffetta et al. 2000). A non-
environmental exposure—radia tion treatment 
of childhood cancer—causes major increases 
in later mortality from other cancers (exclud-
ing recurrence of the treated cancer) as well 
as from non cancer outcomes. A recent report 
from the Childhood Cancer Survivor Study 
showed that mortality from other cancers was 
increased [relative risk (RR) = 2.9; 95% CI: 
2.1, 4.2] and that mortality from cardiac causes 
(RR = 3.3; 95% CI: 2.0, 5.5) and “other” 
causes (RR = 2.0; 95% CI: 1.3, 3.1) were also 
increased (Mertens et al. 2008). Increased can-
cer mortality has also been demonstrated in 
atomic-bomb survivors exposed in utero or as 
young children (Preston et al. 2008). Excluding 
these fairly rare and specific high-dose radiation 
exposure scenarios, our findings suggest that 
early-life exposure to arsenic in drinking water 
results in greater increases in mortality in adults 
< 50 years of age than those attributable to any 
other early-life environ mental exposure.
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Conclusions
To our knowledge, this is the first investigation 
of all causes of death in young adults follow-
ing early-life exposure to arsenic in drinking 
water. In those exposed to water arsenic con-
centrations of approximately 870 µg/L, we 
identified pronounced increases in mortality in 
young adults 30–49 years of age from cancers 
of the bladder, larynx, and liver and from renal 
diseases associated with chronic renal failure. 
Taken together with the increased mortality 
from other causes (Smith et al. 2006; Yuan 
et al. 2007, 2010), the magnitude and extent 
of the increased mortality we have identified 
are without precedent for any early-life envi-
ronmental exposure. Our findings need to be 
confirmed in other populations, but they add 
strong support for efforts to reduce popula-
tion exposure to arsenic in drinking water, 
 particularly during pregnancy and childhood.
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